Chen Can, Huang Mengjun, He Haiqing, Wu Shuiqing, Liu Mingke, He Jun, Zang Hongjing, Xu Ran
Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China.
Front Med (Lausanne). 2022 Mar 3;9:831952. doi: 10.3389/fmed.2022.831952. eCollection 2022.
To share our experience in the diagnosis and treatment of an inflammatory myofibroblastic tumor of the urinary bladder (IMTUB).
A database searches in the pathology archives by using the term "inflammatory myofibroblastic tumor" and" bladder" in our hospital department of pathology from 2010 to 2021. Patient characteristics, clinical features, histopathological results, immunohistochemical staining results, and treatment outcomes were reviewed.
Fourteen cases of IMTUB were retrieved. The mean age was 44.7 ± 18.9 years (range 12-74). Nine (64.3%) of the patients presented with hematuria, followed by seven (50%) with odynuria, five (35.7%) with urgent urination, and one (7.1%) with dysuria. Ten (71.4%) of the patients were treated with partial cystectomy (PC), three (21.4%) with transurethral resection of bladder tumor (TURBT), and one (7.1%) with radical cystectomy (RC). Histopathologically, eight (57.1%) had a compact spindle cell pattern. Anaplastic lymphoma kinase (ALK) staining was positive in six (75%) of 8 cases. During a mean follow-up period of 43.9 ± 38 months (range 3-117), a patient had recurrence within half a month. Then, the patient was treated with further TURBT surgery and had no recurrence within 6 months. Thirteen of the patients had no local recurrence or distant metastasis.
Inflammatory myofibroblastic tumor of the urinary bladder (IMTUB) is clinically rare and has a good prognosis. The disease is mainly treated with surgery to remove the tumor completely. It can easily be misdiagnosed as bladder urothelial carcinoma, leiomyosarcoma, or rhabdomyosarcoma, which may result in overtreatment and poor quality of life of patients.
分享我们在膀胱炎性肌纤维母细胞瘤（IMTUB）诊断和治疗方面的经验。
在我院病理科2010年至2021年的病理档案中，使用“炎性肌纤维母细胞瘤”和“膀胱”进行数据库检索。回顾患者的特征、临床特征、组织病理学结果、免疫组化染色结果及治疗结果。
共检索到14例IMTUB患者。平均年龄为44.7±18.9岁（范围12 - 74岁）。9例（64.3%）患者出现血尿，其次7例（50%）出现尿痛，5例（35.7%）出现尿急，1例（7.1%）出现排尿困难。10例（71.4%）患者接受了膀胱部分切除术（PC），3例（21.4%）接受了经尿道膀胱肿瘤切除术（TURBT），1例（7.1%）接受了根治性膀胱切除术（RC）。组织病理学上，8例（57.1%）表现为致密梭形细胞模式。8例中的6例（75%）间变性淋巴瘤激酶（ALK）染色呈阳性。在平均随访期43.9±38个月（范围3 - 117个月）内，1例患者在半个月内复发。随后，该患者接受了进一步的TURBT手术，6个月内未再复发。13例患者无局部复发或远处转移。
膀胱炎性肌纤维母细胞瘤（IMTUB）临床罕见，预后良好。该病主要通过手术彻底切除肿瘤进行治疗。它很容易被误诊为膀胱尿路上皮癌、平滑肌肉瘤或横纹肌肉瘤，这可能导致过度治疗并影响患者生活质量。
